Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the morphological and visual acuity outcomes
associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for
treatment of diabetic macular edema.
Phase:
Phase 2
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo